Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Virtual

  1. Events
  2. Venues
  3. Virtual
Events at this venue
Today

Contractors

Timesheet Portal

Clients
Legal
Contact Us

Copyright © 2024 | Hlx Life Sciences

Site by theLEAP

Go to Top